UNSPSC 51142511: Entacapone

This classification denotes an antiparkinsonian agent with the molecular formula C14H15N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4975G9NM6T, chemically known as 2-propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl- but generally known as entacapone, which bears US NIH Compound Identifier 5281081. European Medicines Agency schedules Entacapone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06552MIG.

UNSPSC 51142511 Entacapone is a Commodity code nominally covering a specific Parkinson's disease medication, but recent state and local opportunities tagged under this code show little activity directly related to entacapone itself. Instead, the code appears in solicitations for broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. State and local health departments, cooperative purchasing alliances, and county health agencies are the issuing bodies, with participation spanning multiple states through multistate cooperative purchasing vehicles. The work involves sourcing and distributing pharmaceuticals and related medical products to government health facilities, with vendors responsible for compliance with FDA requirements, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), pricing transparency, and supply chain documentation through authorized wholesalers.

Recent activity shows Minnesota's multistate cooperative (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026 and a two-year initial term. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the due date notation appears inconsistent with the posting date. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs to gather vendor capabilities on implementing therapeutic pharmacy initiatives outside traditional pharmacy benefit manager and group purchasing organization channels. Activity is concentrated in Texas, Florida, and the Upper Midwest, with cooperative purchasing vehicles expanding reach across multiple states.